Developments in trial design A methodological perspective Rolf H.H. - - PowerPoint PPT Presentation

developments in trial design
SMART_READER_LITE
LIVE PREVIEW

Developments in trial design A methodological perspective Rolf H.H. - - PowerPoint PPT Presentation

Developments in trial design A methodological perspective Rolf H.H. Groenwold RSNN meeting, 17 April 2019 1 18-Jun-19 Trial design used to be easy Challenges RWE Patient subgroups Small populations Rapid


slide-1
SLIDE 1

A methodological perspective Rolf H.H. Groenwold

RSNN meeting, 17 April 2019

Developments in trial design

1 18-Jun-19

slide-2
SLIDE 2

Trial design used to be ‘easy’

slide-3
SLIDE 3

Challenges

▪ RWE ▪ Patient subgroups ▪ Small populations ▪ Rapid developments ▪ Costly infrastructure

slide-4
SLIDE 4

Adaptations to conventional trial design

(not exhaustive) Challenge Adaptation RWE Pragmatism

  • ‘real-world’ populations
  • ‘real-world’ physicians
  • ‘real-world’ monitoring (wearables)
  • Trials within cohorts (Twics)

Patient subgroups / small populations

  • N-of-1 studies
  • Single arm studies
  • Informed analysis
  • Co-enrolment

Rapid Developments

  • Platform trial
  • Master protocol

Costs

  • Learning healthcare system (LHS)
slide-5
SLIDE 5

Pragmatic trials

slide-6
SLIDE 6

Pragmatic trials

Example: EHR-based trials

  • Recruitment
  • Outcome assessment
  • Safety monitoring(?)

GCP vs. pragmatism

Mentz e.a., Circulation 2016; Ford & Norrie, NEJM 2016; Thorpe e.a., CMAJ 2009

slide-7
SLIDE 7

Van Staa e.a., Health Technol Assess 2014

slide-8
SLIDE 8

BMJ 2019;364:l1092

slide-9
SLIDE 9

Trials within cohorts

Infrastructure for trials

  • Staged recruitment
  • Staged informed consent
  • Consent to be randomized
  • Control arm remains ignorant

www.twics.global/the-design-twics

slide-10
SLIDE 10

Possible advantages:

  • RWE

Possible limitations:

  • RWE

Pragmatic trials

slide-11
SLIDE 11

N-of-1 Trials

slide-12
SLIDE 12

N-of-1 Trials

Stunnenberg e.a., JAMA 2017

slide-13
SLIDE 13

Possible advantages:

  • Small samples
  • Adaptive

Possible limitations:

  • Deblinding (gastrointestinal adverse reactions)
  • Only for chronic/stable diseases and treatment with rapid response

N-of-1 Trials

slide-14
SLIDE 14

Informed analysis

slide-15
SLIDE 15

Informed analysis

Laptook e.a., JAMA 2017

slide-16
SLIDE 16

Informed analysis

Laptook e.a., JAMA 2017

slide-17
SLIDE 17

Possible advantages:

  • Small samples (statistical efficiency due to external information)

Possible limitations:

  • Willingness to accept external information?

Informed analysis

slide-18
SLIDE 18
slide-19
SLIDE 19

Possible advantages:

  • Multiple studies in small populations

Possible limitations:

  • Contamination
  • Burden of participation

Co-enrollment

slide-20
SLIDE 20

Platform trial

Woodcock e.a., NEJM 2017

slide-21
SLIDE 21

Umbrella trial

Woodcock e.a., NEJM 2017

slide-22
SLIDE 22

Basket trial

Woodcock e.a., NEJM 2017

slide-23
SLIDE 23

Master protocols

Possible advantages:

  • Trial infrastructure
  • Improve recruitment
  • Access to small populations (?)
  • Respond quickly to new developments

Possible limitations:

  • Institutional review process (?)
  • Costs to maintain infrastructure (?)
slide-24
SLIDE 24

Learning Healthcare system

slide-25
SLIDE 25
slide-26
SLIDE 26
slide-27
SLIDE 27
slide-28
SLIDE 28
slide-29
SLIDE 29

r.h.h.groenwold@lumc.nl